Thelansis

Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) Market Outlook Thelansis’s “Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outloo...

Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) Market Outlook Thelansis’s “Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Adult T-cell Lymphoma/Leukemia (ATL) Overview Relapsed or Refractory Adult T-cell lymphoma/leukemia (ATL) is a rare lymphoproliferative neoplasm of mature CD4+ CD25+ T cells caused by infection with the retrovirus human T-lymphotropic virus type 1 (HTLV-1). Nearly 90% of patients experience relapse, and co...

  Relapsed or Refractory Adult T-cell lymphoma/leukemia (ATL) is a rare lymphoproliferative neoplasm of mature CD4+ CD25+ T cells caused by infection with the retrovirus human T-lymphotropic virus type 1 (HTLV-1). Nearly 90% of patients experience relapse and consolidation of the first remission with allogeneic stem-cell transplantation is strongly considered. The aggressive subtypes of ATL carry some of the poorest prognoses of any of the non-Hodgkin lymphomas. In an extensive retrospective analysis, patients with ATL had 5-year failure-free and overall survival (OS) of only 12% and 14%, respectively. However, the clinical course can vary with this disease's chronic and smoldering variants. In patients without histologically proven tumor lesions, at least 5% of circulating abnormal T lymphocytes are required to diagnose ATL. These cells typically express the surface T-cell lymphocytic markers CD2, CD4, CD5, CD29, CD45RO, and T-cell receptor (TCR) αβ and are usually negative for ...